Stephen M Scott - Dept Invest Canc Therapeut, Univ Texas MD Anderson Canc Ctr

基本信息

浏览量：8

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 25 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Anti-tumor Activity and Biomarker Analysis for TROP2-antibody Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models

Funda Meric-Bernstam,Erkan Yuca,Kurt W. Evans, Ming Zhao,Takanori Maejima,Tsuyoshi Karibe,Maria Gabriela Raso,Ximing Tang,Xiaofeng Zheng,Yasmeen Qamar Rizvi,Argun Akcakanat,Stephen M. Scott,Bailiang Wang,Lauren A. Byers,Debu Tripathy,Daisuke Okajima,Senthil Damodaran

CLINICAL CANCER RESEARCHno. 3 (2025): 573-587

引用0浏览0WOS引用

Utilizing Patient-derived Xenografts to Model Precision Oncology for Biliary Tract Cancer

Clinical cancer research an official journal of the American Association for Cancer Researchno. 2 (2025): 387-402

引用0浏览0WOS引用

Convergent MAPK Pathway Alterations Mediate Acquired Resistance to FGFR Inhibitors in FGFR2 Fusion-Positive Cholangiocarcinoma

Timothy P. Diperi,Ming Zhao,Kurt W. Evans,Kaushik Varadarajan,Tyler Moss,Stephen Scott,Michael P. Kahle, Charnel C. Byrnes,Huiqin Chen,Sunyoung S. Lee,Abdel-Baset Halim,Hiroshi Hirai,Volker Wacheck,Lawrence N. Kwong,Jordi Rodon,Milind Javle,Funda Meric-Bernstam

JOURNAL OF HEPATOLOGY（2024）

引用2浏览0WOS引用

Table S1, Figure S1,Table S2, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Figure S8, Figure S9 from Combining Neratinib with CDK4/6, Mtor, and MEK Inhibitors in Models of HER2-positive Cancer

Ming Zhao,Stephen Scott,Kurt W. Evans,Erkan Yuca,Turcin Saridogan,Xiaofeng Zheng,Heping Wang,Anil Korkut,Christian X. Cruz Pico,Mehmet Demirhan,Bryce Kirby,Scott Kopetz,Irmina Diala,Alshad S. Lalani,Sarina Piha-Paul,Funda Meric-Bernstam

crossref（2024）

引用0浏览0引用

Supplementary Data from Combining Neratinib with CDK4/6, Mtor, and MEK Inhibitors in Models of HER2-positive Cancer

crossref（2024）

引用0浏览0引用

33P Antitumor Activity of TROP2 Antibody Drug Conjugate Datopotamab Deruxtecan in Chemotherapy-Resistant Breast Cancer Models

F. Meric-Bernstam,E. Yuca,K. Evans,M. Zhao,M.G. Raso,T. Maejima,X. Zheng,Y. Rizvi,A. Akcakanat,S. Scott,B. Wang,L.A. Byers,D. Tripathy, D. Okajima,S. Damodaran

ESMO Open（2023）

引用0浏览0引用

Efficacy of Futibatinib, an Irreversible Fibroblast Growth Factor Receptor Inhibitor, in FGFR-altered Breast Cancer

Turcin Saridogan,Argun Akcakanat,Ming Zhao,Kurt W. Evans,Erkan Yuca,Stephen Scott,Bryce P. Kirby,Xiaofeng Zheng,Min Jin Ha,Huiqin Chen,Patrick K. S. Ng,Timothy P. DiPeri,Gordon B. Mills,Jordi Rodon Ahnert,Senthil Damodaran,Funda Meric-Bernstam

SCIENTIFIC REPORTS（2023）

引用5浏览0WOSNATURE引用

Figure S1 from A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors

Kurt W. Evans,Erkan Yuca,Argun Akcakanat,Stephen M. Scott,Natalia Paez Arango,Xiaofeng Zheng,Ken Chen,Coya Tapia,Emily Tarco,Agda K. Eterovic,Dalliah M. Black,Jennifer K. Litton,Timothy A. Yap,Debu Tripathy,Gordon B. Mills,Funda Meric-Bernstam

openalex（2023）

引用0浏览0引用

Antitumor Activity of the ATR Inhibitor Elimusertib in Patient-Derived Xenograft Models with DNA Damage Response Pathway Alterations

Kaushik Varadarajan, Christian X. Pico,Kurt Evans,Maria G. Raso,Yasmeen Rizvi,Xiaofeng Zheng,Timothy P. Diperi,Bailiang Wang,Stephen Scott,Ming Zhao,Argun Akcakanat,Antje M. Wengner,Timothy A. Yap,Funda Meric-Bernstam

CANCER RESEARCH（2023）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn